1
|
Malone R, Savage S, Crowley V, Hennessy M, O’Connor P, Kennedy C. Risk Factors and Modifiers for Cardiovascular Disease Assessment of Patients with Heterozygous Familial Hypercholesterolaemia. J Clin Med 2024; 13:2270. [PMID: 38673543 PMCID: PMC11051062 DOI: 10.3390/jcm13082270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Revised: 03/13/2024] [Accepted: 04/07/2024] [Indexed: 04/28/2024] Open
Abstract
Background: The assessment of the risk of cardiovascular disease (CVD) in patients with heterozygous familial hypercholesterolemia (HeFH) is determined by conventional risk factors. However, factors modifying CVD, or risk modifiers, beyond conventional risk factors may inform their CVD risk assessment and the subsequent use of new therapies. This work identifies and characterises patients within a lipid clinic cohort with regards to conventional CVD risk factors and risk modifiers with a focus on those with HeFH. Methods: A study of consecutive adult patients attending our specialist lipid clinic was performed over a six-month period. The patient data recorded included demographics, clinical characteristics, risk factors and risk modifiers, biochemical profiles and genetic testing results. Risk modifiers were identified based on ESC/EAS guidance, and those with HeFH were compared to those without. Results: A total of 370 patients were included. Of these, 98 HeFH patients were identified (26%). Then, 52% of HeFH patients were stratified into the very-high risk category due to the presence of CVD risk factors. Risk modifiers were present in 73%. These included a family history of premature CVD (56%), obesity (28%), a sedentary lifestyle (13%) and a major psychiatric disorder (12%). Compared to the rest of the cohort, those with HeFH were less likely to have hypertension and more likely to have a family history of premature CVD. Conclusions: Half of patients with HeFH are categorised as having very high CV risk. Consideration of risk modifiers, particularly a family history of premature CV disease, increases this very-high-risk category further. This may have implications for the clinical application and access to novel treatments.
Collapse
Affiliation(s)
- Richard Malone
- School of Medicine, Trinity College Dublin, D08 W9RT Dublin, Ireland; (R.M.); (M.H.); (P.O.)
| | - Sarah Savage
- Department of Biochemistry Department, St James’s Hospital, D08 W9RT Dublin, Ireland; (S.S.); (V.C.)
| | - Vivion Crowley
- Department of Biochemistry Department, St James’s Hospital, D08 W9RT Dublin, Ireland; (S.S.); (V.C.)
| | - Martina Hennessy
- School of Medicine, Trinity College Dublin, D08 W9RT Dublin, Ireland; (R.M.); (M.H.); (P.O.)
- Department of Pharmacology & Therapeutics, St James’s Hospital, D08 W9RT Dublin, Ireland
| | - Patricia O’Connor
- School of Medicine, Trinity College Dublin, D08 W9RT Dublin, Ireland; (R.M.); (M.H.); (P.O.)
- Department of Pharmacology & Therapeutics, St James’s Hospital, D08 W9RT Dublin, Ireland
| | - Cormac Kennedy
- School of Medicine, Trinity College Dublin, D08 W9RT Dublin, Ireland; (R.M.); (M.H.); (P.O.)
- Department of Pharmacology & Therapeutics, St James’s Hospital, D08 W9RT Dublin, Ireland
| |
Collapse
|
2
|
Lubala TK, Kayembe-Kitenge T, Mubungu G, Lumaka A, Kanteng G, Savage S, Luboya O, Hagerman R, Devriendt K, Lukusa-Tshilobo P. Usefulness of automated image analysis for recognition of the fragile X syndrome gestalt in Congolese subjects. Eur J Med Genet 2023; 66:104819. [PMID: 37532084 DOI: 10.1016/j.ejmg.2023.104819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 07/16/2023] [Accepted: 07/30/2023] [Indexed: 08/04/2023]
Abstract
BACKGROUND Computer-aided software such as the facial image diagnostic aid (FIDA) and Face2Gene has been developed to perform pattern recognition of facial features with promising clinical results. The aim of this pilot study was to test Face2Gene's recognition performance on Bantu Congolese subjects with Fragile X syndrome (FXS) as compared to Congolese subjects with intellectual disability but without FXS (non-FXS). METHOD Frontal facial photograph from 156 participants (14 patients with FXS and 142 controls) predominantly young-adults to adults, median age 18.9 age range 4-39yo, were uploaded. Automated face analysis was conducted by using the technology used in proprietary software tools called Face2Gene CLINIC and Face2Gene RESEARCH (version 17.6.2). To estimate the statistical power of the Face2Gene technology in distinguishing affected individuals from controls, a cross validation scheme was used. RESULTS The similarity seen in the upper facial region (of males and females) is greater than the similarity seen in other parts of the face. Binary comparison of subjects with FXS versus non-FXS and subjects with FXS versus subjects with Down syndrome reveal an area under the curve values of 0.955 (p = 0.002) and 0.986 (p = 0.003). CONCLUSION The Face2Gene algorithm is separating well between FXS and Non-FXS subjects.
Collapse
Affiliation(s)
- Toni Kasole Lubala
- Division of Dysmorphology & Birth Defects, Department of Pediatrics, University of Lubumbashi, Democratic Republic of the Congo
| | - Tony Kayembe-Kitenge
- Unit of Toxicology and Environment, School of Public Health, University of Lubumbashi, Democratic Republic of the Congo; Center for Environment and Health, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; Higher Institute of Medical Techniques, Lubumbashi, Democratic Republic of the Congo.
| | - Gerrye Mubungu
- Department of Pediatrics, Faculty of Medicine, University of Kinshasa, Democratic Republic of the Congo; Center for Human Genetics, National Institute for Biomedical Research (NIBR), Democratic Republic of the Congo; Center for Human Genetics, University Hospital Leuven, University of Leuven, Belgium
| | - Aimé Lumaka
- Department of Pediatrics, Faculty of Medicine, University of Kinshasa, Democratic Republic of the Congo; Center for Human Genetics, National Institute for Biomedical Research (NIBR), Democratic Republic of the Congo; Center for Human Genetics, University Hospital Leuven, University of Leuven, Belgium; Department of Biomedical and Preclinical Sciences, GIGA-Rm Laboratory of Human Genetics, University of Liège, Liège, Belgium
| | - Gray Kanteng
- Division of Dysmorphology & Birth Defects, Department of Pediatrics, University of Lubumbashi, Democratic Republic of the Congo
| | | | - Oscar Luboya
- Division of Dysmorphology & Birth Defects, Department of Pediatrics, University of Lubumbashi, Democratic Republic of the Congo; Higher Institute of Medical Techniques, Lubumbashi, Democratic Republic of the Congo
| | - Randi Hagerman
- Department of Pediatrics, MIND Institute, University of California Davis Medical Center, Sacramento, CA, USA
| | - Koenraad Devriendt
- Center for Human Genetics, University Hospital Leuven, University of Leuven, Belgium
| | - Prosper Lukusa-Tshilobo
- Department of Pediatrics, Faculty of Medicine, University of Kinshasa, Democratic Republic of the Congo; Center for Human Genetics, National Institute for Biomedical Research (NIBR), Democratic Republic of the Congo; Center for Human Genetics, University Hospital Leuven, University of Leuven, Belgium
| |
Collapse
|
3
|
Stone B, Savage S, McBride K, Kaler S. eP256: Intrafamilial variability in chromosome 2q13 microdeletion: Case report and review of the literature. Genet Med 2022. [DOI: 10.1016/j.gim.2022.01.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
4
|
Garcia-Cortadella R, Schwesig G, Jeschke C, Illa X, Gray AL, Savage S, Stamatidou E, Schiessl I, Masvidal-Codina E, Kostarelos K, Guimerà-Brunet A, Sirota A, Garrido JA. Author Correction: Graphene active sensor arrays for long-term and wireless mapping of wide frequency band epicortical brain activity. Nat Commun 2021; 12:2568. [PMID: 33931663 PMCID: PMC8087696 DOI: 10.1038/s41467-021-23078-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- R Garcia-Cortadella
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193, Barcelona, Spain
| | - G Schwesig
- Bernstein Center for Computational Neuroscience Munich, Faculty of Medicine, Ludwig-Maximilians Universität München, Planegg-Martinsried, Germany
| | - C Jeschke
- Multi Channel Systems (MCS) GmbH, Reutlingen, Germany
| | - X Illa
- Instituto de Microelectrónica de Barcelona, IMB-CNM (CSIC), Esfera UAB, Bellaterra, Spain.,Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
| | - Anna L Gray
- Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - S Savage
- Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - E Stamatidou
- Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - I Schiessl
- Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK
| | - E Masvidal-Codina
- Instituto de Microelectrónica de Barcelona, IMB-CNM (CSIC), Esfera UAB, Bellaterra, Spain.,Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
| | - K Kostarelos
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193, Barcelona, Spain.,Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - A Guimerà-Brunet
- Instituto de Microelectrónica de Barcelona, IMB-CNM (CSIC), Esfera UAB, Bellaterra, Spain.,Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
| | - A Sirota
- Bernstein Center for Computational Neuroscience Munich, Faculty of Medicine, Ludwig-Maximilians Universität München, Planegg-Martinsried, Germany.
| | - J A Garrido
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193, Barcelona, Spain. .,ICREA, Pg. Lluís Companys 23, 08010, Barcelona, Spain.
| |
Collapse
|
5
|
Rasheed E, Savage S, Walsh E, Brazil N, Ralph N, Gorman PO, Crowley V. Porphyria cutanea tarda precipitated by ovarian stimulation during oocyte retrieval in a genetically susceptible female. Ann Clin Biochem 2021; 58:251-256. [PMID: 33393347 DOI: 10.1177/0004563220988037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We report a case of 33-year-old female with underlying genetic susceptibility for familial porphyria cutanea tarda due to novel UROD variant (c.636 + 2 dupT) unmasked by transient exposure to supraphysiological oestrogen concentrations following a single cycle of successful controlled ovarian stimulation for oocyte retrieval. Use of oral oestrogen in the form of oral contraceptive pills and hormone replacement therapy has been well known to trigger active porphyria cutanea tarda phenotype in susceptible women. However, to date, the emergence of clinically overt porphyria cutanea tarda has not been reported in association with fertility treatment in the literature before.
Collapse
Affiliation(s)
- Erum Rasheed
- Biochemistry Department, St. James's Hospital, Dublin, Ireland
| | - Sarah Savage
- Biochemistry Department, St. James's Hospital, Dublin, Ireland
| | - Elena Walsh
- Biochemistry Department, St. James's Hospital, Dublin, Ireland
| | - Nadia Brazil
- Biochemistry Department, St. James's Hospital, Dublin, Ireland
| | - Nicola Ralph
- Institute of Dermatologists, Blackrock Clinic/Mater Private, Dublin, Ireland
| | - Peter O' Gorman
- Haematology Department, Mater Private Hospital, Dublin, Ireland
| | - Vivion Crowley
- Biochemistry Department, St. James's Hospital, Dublin, Ireland
| |
Collapse
|
6
|
Garcia-Cortadella R, Schwesig G, Jeschke C, Illa X, Gray AL, Savage S, Stamatidou E, Schiessl I, Masvidal-Codina E, Kostarelos K, Guimerà-Brunet A, Sirota A, Garrido JA. Graphene active sensor arrays for long-term and wireless mapping of wide frequency band epicortical brain activity. Nat Commun 2021; 12:211. [PMID: 33431878 PMCID: PMC7801381 DOI: 10.1038/s41467-020-20546-w] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Accepted: 12/08/2020] [Indexed: 01/29/2023] Open
Abstract
Graphene active sensors have demonstrated promising capabilities for the detection of electrophysiological signals in the brain. Their functional properties, together with their flexibility as well as their expected stability and biocompatibility have raised them as a promising building block for large-scale sensing neural interfaces. However, in order to provide reliable tools for neuroscience and biomedical engineering applications, the maturity of this technology must be thoroughly studied. Here, we evaluate the performance of 64-channel graphene sensor arrays in terms of homogeneity, sensitivity and stability using a wireless, quasi-commercial headstage and demonstrate the biocompatibility of epicortical graphene chronic implants. Furthermore, to illustrate the potential of the technology to detect cortical signals from infra-slow to high-gamma frequency bands, we perform proof-of-concept long-term wireless recording in a freely behaving rodent. Our work demonstrates the maturity of the graphene-based technology, which represents a promising candidate for chronic, wide frequency band neural sensing interfaces.
Collapse
Affiliation(s)
- R Garcia-Cortadella
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193, Barcelona, Spain
| | - G Schwesig
- Bernstein Center for Computational Neuroscience Munich, Faculty of Medicine, Ludwig-Maximilians Universität München, Planegg-Martinsried, Germany
| | - C Jeschke
- Multi Channel Systems (MCS) GmbH, Reutlingen, Germany
| | - X Illa
- Instituto de Microelectrónica de Barcelona, IMB-CNM (CSIC), Esfera UAB, Bellaterra, Spain
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
| | - Anna L Gray
- Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - S Savage
- Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - E Stamatidou
- Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - I Schiessl
- Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK
| | - E Masvidal-Codina
- Instituto de Microelectrónica de Barcelona, IMB-CNM (CSIC), Esfera UAB, Bellaterra, Spain
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
| | - K Kostarelos
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193, Barcelona, Spain
- Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
| | - A Guimerà-Brunet
- Instituto de Microelectrónica de Barcelona, IMB-CNM (CSIC), Esfera UAB, Bellaterra, Spain
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
| | - A Sirota
- Bernstein Center for Computational Neuroscience Munich, Faculty of Medicine, Ludwig-Maximilians Universität München, Planegg-Martinsried, Germany.
| | - J A Garrido
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193, Barcelona, Spain.
- ICREA, Pg. Lluís Companys 23, 08010, Barcelona, Spain.
| |
Collapse
|
7
|
Gillette M, Satpathy S, Cao S, Dhanasekaran S, Vasaikar S, Krug K, Petralia F, Li Y, Liang WW, Reva B, Hong R, Savage S, Getz G, Li Q, Zhang B, Rodriguez H, Ruggles K, Robles A, Clauser K, Govindan R, Wang P, Nesvizhskii A, Ding L, Mani D, Carr S. A02 Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2019.12.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Savage S, Baker J, Butler C, Hodges J, Zeman A. Long-term prognosis of transient epileptic amnesia: Evidence from the time project. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Savage S, Piguet O, Hodges J. Relearning in semantic dementia: Word retraining programs to help rebuild vocabulary. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Moss P, Howlin P, Savage S, Bolton P, Rutter M. Self and informant reports of mental health difficulties among adults with autism findings from a long-term follow-up study. Autism 2015; 19:832-41. [DOI: 10.1177/1362361315585916] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Data on psychiatric problems in adults with autism are inconsistent, with estimated rates ranging from around 25% to over 75%. We assessed difficulties related to mental health in 58 adults with autism (10 females, 48 males; mean age 44 years) whom we have followed over four decades. All were of average non-verbal intelligence quotient when diagnosed as children. Overall ratings of mental health problems were based on data from the Family History Schedule (Bolton et al., 1994). Informant reports indicated that many of the cohort (44%) had experienced no mental health problems in adulthood; 28% had experienced mild to moderate difficulties, 23% had severe and 5% very severe problems. Depression was the most commonly reported problem. Among those adults ( n = 22) able to report on their own mental state, again many (45%) reported no mental health problems, although 27% reported very severe mental health problems related to anxiety, depression and/or obsessive–compulsive symptoms. Informant ratings of poor mental health were not associated with gender, severity of autism in childhood, or child or adult intelligence quotient, but there were small correlations with overall social functioning (rho = 0.34) and current autism severity (rho = 0.37). The findings highlight the difficulties of assessing mental health problems in adults with autism and the need for appropriately validated measures.
Collapse
Affiliation(s)
| | - Patricia Howlin
- King’s College London, UK
- The University of Sydney, Australia
- Joint first authors
| | | | | | | |
Collapse
|
11
|
|
12
|
Graves E, Savage S. Financial Pasts, Presents, and Futures of Community College Students of a Personal Finance Course. Journal of Business & Finance Librarianship 2015. [DOI: 10.1080/08963568.2015.977132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
|
14
|
Classen CF, William D, Linnebacher M, Farhod A, Kedr W, Elsabe B, Fadel S, Van Gool S, De Vleeschouwer S, Koks C, Garg A, Ehrhardt M, Riva M, De Vleeschouwer S, Agostinis P, Graf N, Van Gool S, Yao TW, Yoshida Y, Zhang J, Ozawa T, James D, Nicolaides T, Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E, Van Gool S, De Vleeschouwer S, Al-Kofide A, Al-Shail E, Khafaga Y, Al-Hindi H, Dababo M, Haq AU, Anas M, Barria MG, Siddiqui K, Hassounah M, Ayas M, van Zanten SV, Jansen M, van Vuurden D, Huisman M, Vugts D, Hoekstra O, van Dongen G, Kaspers G, Cockle J, Ilett E, Scott K, Bruning-Richardson A, Picton S, Short S, Melcher A, Benesch M, Warmuth-Metz M, von Bueren AO, Hoffmann M, Pietsch T, Kortmann RD, Eyrich M, Graf N, Rutkowski S, Fruhwald MC, Faber J, Kramm C, Porkholm M, Valanne L, Lonnqvist T, Holm S, Lannering B, Riikonen P, Wojcik D, Sehested A, Clausen N, Harila-Saari A, Schomerus E, Thorarinsdottir HK, Lahteenmaki P, Arola M, Thomassen H, Saarinen-Pihkala UM, Kivivuori SM, Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Morrison A, Bouffet E, Bartels U, Becher O, Hawkins C, Gould TWA, Rahman CV, Smith SJ, Barrett DA, Shakesheff KM, Grundy RG, Rahman R, Barua N, Cronin D, Gill S, Lowisl S, Hochart A, Maurage CA, Rocourt N, Vinchon M, Kerdraon O, Escande F, Grill J, Pick VK, Leblond P, Burzynski G, Janicki T, Burzynski S, Marszalek A, Ramani N, Zaky W, Kannan G, Morani A, Sandberg D, Ketonen L, Maher O, Corrales-Medina F, Meador H, Khatua S, Brassesco M, Delsin L, Roberto G, Silva C, Ana L, Rego E, Scrideli C, Umezawa K, Tone L, Kim SJ, Kim CY, Kim IA, Han JH, Choi BS, Ahn HS, Choi HS, Haque F, Rahman R, Layfield R, Grundy R, Gandola L, Pecori E, Biassoni V, Schiavello E, Chiruzzi C, Spreafico F, Modena P, Bach F, Pignoli E, Massimino M, Drogosiewicz M, Dembowska-Baginska B, Jurkiewicz E, Filipek I, Perek-Polnik M, Swieszkowska E, Perek D, Bender S, Jones DT, Warnatz HJ, Hutter B, Zichner T, Gronych J, Korshunov A, Eils R, Korbel JO, Yaspo ML, Lichter P, Pfister SM, Yadavilli S, Becher OJ, Kambhampati M, Packer RJ, Nazarian J, Lechon FC, Fowkes L, Khabra K, Martin-Retortillo LM, Marshall LV, Vaidya S, Koh DM, Leach MO, Pearson AD, Zacharoulis S, Lechon FC, Fowkes L, Khabra K, Martin-Retortillo LM, Marshall LV, Schrey D, Barone G, Vaidya S, Koh DM, Pearson AD, Zacharoulis S, Panditharatna E, Stampar M, Siu A, Gordish-Dressman H, Devaney J, Kambhampati M, Hwang EI, Packer RJ, Nazarian J, Chung AH, Mittapalli RK, Elmquist WF, Becher OJ, Castel D, Debily MA, Philippe C, Truffaux N, Taylor K, Calmon R, Boddaert N, Le Dret L, Saulnier P, Lacroix L, Mackay A, Jones C, Puget S, Sainte-Rose C, Blauwblomme T, Varlet P, Grill J, Entz-Werle N, Maugard C, Bougeard G, Nguyen A, Chenard MP, Schneider A, Gaub MP, Tsoli M, Vanniasinghe A, Luk P, Dilda P, Haber M, Hogg P, Ziegler D, Simon S, Tsoli M, Vanniasinghe A, Monje M, Gurova K, Gudkov A, Haber M, Ziegler D, Zapotocky M, Churackova M, Malinova B, Zamecnik J, Kyncl M, Tichy M, Puchmajerova A, Stary J, Sumerauer D, Boult J, Vinci M, Taylor K, Perryman L, Box G, Jury A, Popov S, Ingram W, Monje M, Eccles S, Jones C, Robinson S, Emir S, Demir HA, Bayram C, Cetindag F, Kabacam GB, Fettah A, Boult J, Li J, Vinci M, Jury A, Popov S, Jamin Y, Cummings C, Eccles S, Bamber J, Sinkus R, Jones C, Robinson S, Nandhabalan M, Bjerke L, Vinci M, Burford A, Ingram W, Mackay A, von Bueren A, Baudis M, Clarke P, Collins I, Workman P, Jones C, Taylor K, Mackay A, Vinci M, Popov S, Ingram W, Entz-Werle N, Monje M, Olaciregui N, Mora J, Carcaboso A, Bullock A, Jones C, Vinci M, Mackay A, Burford A, Taylor K, Popov S, Ingram W, Monje M, Alonso M, Olaciregui N, de Torres C, Cruz O, Mora J, Carcaboso A, Jones C, Filipek I, Drogosiewicz M, Perek-Polnik M, Swieszkowska E, Dembowska-Baginska B, Jurkiewicz E, Perek D, Nguyen A, Pencreach E, Mackay A, Moussalieh FM, Guenot D, Namer I, Chenard MP, Jones C, Entz-Werle N, Pollack I, Jakacki R, Butterfield L, Hamilton R, Panigrahy A, Potter D, Connelly A, Dibridge S, Whiteside T, Okada H, Ahsan S, Raabe E, Haffner M, Warren K, Quezado M, Ballester L, Nazarian J, Eberhart C, Rodriguez F, Ramachandran C, Nair S, Quirrin KW, Khatib Z, Escalon E, Melnick S, Classen CF, Hofmann M, Schmid I, Simon T, Maass E, Russo A, Fleischhack G, Becker M, Hauch H, Sander A, Kramm C, Grasso C, Truffaux N, Berlow N, Liu L, Debily MA, Davis L, Huang E, Woo P, Tang Y, Ponnuswami A, Chen S, Huang Y, Hutt-Cabezas M, Warren K, Dret L, Meltzer P, Mao H, Quezado M, van Vuurden D, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Raabe E, Hulleman E, Li XN, Keller C, Spellman PT, Pal R, Grill J, Monje M, Jansen MHA, Sewing ACP, Lagerweij T, Vuchts DJ, van Vuurden DG, Caretti V, Wesseling P, Kaspers GJL, Hulleman E, Cohen K, Raabe E, Pearl M, Kogiso M, Zhang L, Qi L, Lindsay H, Lin F, Berg S, Li XN, Muscal J, Amayiri N, Tabori U, Campbel B, Bakry D, Aronson M, Durno C, Gallinger S, Malkin D, Qaddumi I, Musharbash A, Swaidan M, Bouffet E, Hawkins C, Al-Hussaini M, Rakopoulos P, Shandilya S, McCully C, Murphy R, Akshintala S, Cole D, Macallister RP, Cruz R, Widemann B, Warren K, Salloum R, Smith A, Glaunert M, Ramkissoon A, Peterson S, Baker S, Chow L, Sandgren J, Pfeifer S, Popova S, Alafuzoff I, de Stahl TD, Pietschmann S, Kerber MJ, Zwiener I, Henke G, Kortmann RD, Muller K, von Bueren A, Sieow NYF, Hoe RHM, Tan AM, Chan MY, Soh SY, Hawkins C, Burrell K, Chornenkyy Y, Remke M, Golbourn B, Buczkowicz P, Barzczyk M, Taylor M, Rutka J, Dirks P, Zadeh G, Agnihotri S, Hashizume R, Ihara Y, Andor N, Chen X, Lerner R, Huang X, Tom M, Solomon D, Mueller S, Petritsch C, Zhang Z, Gupta N, Waldman T, James D, Dujua A, Co J, Hernandez F, Doromal D, Hegde M, Wakefield A, Brawley V, Grada Z, Byrd T, Chow K, Krebs S, Heslop H, Gottschalk S, Yvon E, Ahmed N, Truffaux N, Philippe C, Cornilleau G, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Puget S, Geoerger B, Vassal G, Ostman A, Grill J, Parsons DW, Lin F, Trevino LR, Gao F, Shen X, Hampton O, Lindsay H, Kosigo M, Qi L, Baxter PA, Su JM, Chintagumpala M, Dauser R, Adesina A, Plon SE, Li XN, Wheeler DA, Lau CC, Pietsch T, Gielen G, Muehlen AZ, Kwiecien R, Wolff J, Kramm C, Lulla RR, Laskowski J, Goldman S, Gopalakrishnan V, Fangusaro J, Mackay A, Taylor K, Vinci M, Jones C, Kieran M, Fontebasso A, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon L, Corcoran A, Jones D, Sturm D, Johann P, Tomita T, Goldman S, Nagib M, Bendel A, Goumnerova L, Bowers DC, Leonard JR, Rubin JB, Alden T, DiPatri A, Browd S, Leary S, Jallo G, Cohen K, Prados MD, Banerjee A, Carret AS, Ellezam B, Crevier L, Klekner A, Bognar L, Hauser P, Garami M, Myseros J, Dong Z, Siegel PM, Gump W, Ayyanar K, Ragheb J, Khatib Z, Krieger M, Kiehna E, Robison N, Harter D, Gardner S, Handler M, Foreman N, Brahma B, MacDonald T, Malkin H, Chi S, Manley P, Bandopadhayay P, Greenspan L, Ligon A, Albrecht S, Pfister SM, Ligon KL, Majewski J, Gupta N, Jabado N, Hoeman C, Cordero F, Halvorson K, Hawkins C, Becher O, Taylor I, Hutt M, Weingart M, Price A, Nazarian J, Eberhart C, Raabe E, Kantar M, Onen S, Kamer S, Turhan T, Kitis O, Ertan Y, Cetingul N, Anacak Y, Akalin T, Ersahin Y, Mason G, Nazarian J, Ho C, Devaney J, Stampar M, Kambhampati M, Crozier F, Vezina G, Packer R, Hwang E, Gilheeney S, Millard N, DeBraganca K, Khakoo Y, Kramer K, Wolden S, Donzelli M, Fischer C, Petriccione M, Dunkel I, Afzal S, Carret AS, Fleming A, Larouche V, Zelcer S, Johnston DL, Kostova M, Mpofu C, Decarie JC, Strother D, Lafay-Cousin L, Eisenstat D, Fryer C, Hukin J, Bartels U, Bouffet E, Hsu M, Lasky J, Moore T, Liau L, Davidson T, Prins R, Fouladi M, Bartels U, Warren K, Hassal T, Baugh J, Kirkendall J, Doughman R, Leach J, Jones B, Miles L, Hawkins C, Bouffet E, Hargrave D, Grill J, Jones C, Jacques T, Savage S, Goldman S, Leary S, Packer R, Saunders D, Wesseling P, Varlet P, van Vuurden D, Wallace R, Flutter B, Morgenestern D, Hargrave D, Blanco E, Howe K, Lowdell M, Samuel E, Michalski A, Anderson J, Arakawa Y, Umeda K, Watanabe KI, Mizowaki T, Hiraoka M, Hiramatsu H, Adachi S, Kunieda T, Takagi Y, Miyamoto S, Venneti S, Santi M, Felicella MM, Sullivan LM, Dolgalev I, Martinez D, Perry A, Lewis PW, Allis DC, Thompson CB, Judkins AR. HIGH GRADE GLIOMAS AND DIPG. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Affiliation(s)
- S Savage
- Pain Medicine and Intensive Care, Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Hospital, London SW10 9NH, UK
| | - D Ma
- Pain Medicine and Intensive Care, Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Hospital, London SW10 9NH, UK
| |
Collapse
|
16
|
McAleer M, Madenholt-Titley S, Savage S, Gudex T, White J, Ruygrok P. Total ambulatory care (TAC) for day-stay coronary angiography patients (Amsterdam protocol): A positive response with suggested enhancements. Heart Lung Circ 2014. [DOI: 10.1016/j.hlc.2014.04.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Gudex T, Madenholt-Titley S, McAleer M, Savage S, White J, Ruygrok P. Introduction and evaluation of total ambulatory management of patients undergoing coronary angiography and intervention. Heart Lung Circ 2014. [DOI: 10.1016/j.hlc.2014.04.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Howlin P, Savage S, Moss P, Tempier A, Rutter M. Cognitive and language skills in adults with autism: a 40-year follow-up. J Child Psychol Psychiatry 2014; 55:49-58. [PMID: 23848399 DOI: 10.1111/jcpp.12115] [Citation(s) in RCA: 131] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/23/2013] [Indexed: 11/28/2022]
Abstract
BACKGROUND It is well established that very few individuals with autism spectrum disorders (ASD) and an IQ below 70 are able to live independently as adults. However, even amongst children with an IQ in the normal range, outcome is very variable. Childhood factors that predict later stability, improvement or decline in cognitive functioning remain uncertain and, in particular, very little is known about trajectories in later adulthood. METHOD Changes in cognitive and language ability from childhood to adulthood were assessed in 60 individuals with autism, all of whom had an IQ in the average range as children. Mean age in childhood = 6 years (range 2-13 years); mean age in adulthood = 44 years (range 29-64 years). Trajectories of change and factors related to current cognitive abilities were explored. RESULTS For the majority of participants (N = 45, 75%), who were testable both as children and adults, IQ remained very stable and language also improved over time. However, 15 individuals could not be assessed on standard tests as adults and their developmental level could be estimated only on the Vineland Adaptive Behavior Scales. Almost all these adults (apart from one who had suffered a major stroke) showed severe aggressive or self-injurious behaviours; none had ever developed language above a 3-year level, and seven had developed epilepsy. CONCLUSIONS For most individuals with autism who had an IQ in the average range (i.e. ≥ 70) as children, childhood IQ proved a reliable predictor of cognitive functioning well into mid- to- later adulthood. However, a significant minority was no longer testable on standard tests as adults. Their current very low levels of functional ability were generally associated with severe behavioural disturbance and persisting and severe language impairment; 50% of these individuals had also developed epilepsy, pointing to the role of organic brain dysfunction. Implications for early intervention are discussed.
Collapse
Affiliation(s)
- Patricia Howlin
- Department of Psychology, Institute of Psychiatry, London, UK; Faculty of Health Sciences, University of Sydney, NSW, Australia
| | | | | | | | | |
Collapse
|
19
|
Savage S, Gudex T, McAleer M, Ruygrok P, Madenholt-Titley S, White J. Patient experience survey: Total ambulatory management and coronary angiography day stay procedures. Heart Lung Circ 2014. [DOI: 10.1016/j.hlc.2014.04.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
MadenHolt-Titley S, Gudex T, McAleer M, Savage S, White J, Ruygrok P. Reduced sedation in patients undergoing coronary angiography of total ambulatory management. Heart Lung Circ 2014. [DOI: 10.1016/j.hlc.2014.04.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
21
|
Abstract
We report a case study of a semantic dementia patient, whose episodic memory consolidation was tested over a 2-month period. The results reveal that despite early retention of information, the patient lost all explicit information of the newly learnt material after 2 weeks. By contrast, he retained implicit word information even after a 4-week delay. These findings highlight the critical time window of 2-4 weeks in which newly learnt information should be re-encoded in rehabilitations studies. The results also indicate that learnt information can be still accessed with implicit retrieval strategies when explicit retrieval fails.
Collapse
Affiliation(s)
- S Tu
- Neuroscience Research Australia, Sydney, Australia
| | | | | | | | | |
Collapse
|
22
|
Rabbitt L, McDonald C, Savage S, Walter M, Rubis C, Schwartz N. High-performing face recognizers use eye-eye distance and eye-nose distance more than low-performing face recognizers. J Vis 2013. [DOI: 10.1167/13.9.978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
23
|
Howlin P, Moss P, Savage S, Rutter M. Social outcomes in mid- to later adulthood among individuals diagnosed with autism and average nonverbal IQ as children. J Am Acad Child Adolesc Psychiatry 2013; 52:572-81.e1. [PMID: 23702446 DOI: 10.1016/j.jaac.2013.02.017] [Citation(s) in RCA: 245] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2012] [Revised: 02/05/2013] [Accepted: 03/15/2013] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To describe current social functioning in a clinical sample of 60 adults with autism (mean age = 44 years) who were all of average nonverbal IQ (70+) when first diagnosed (mean age = 6.75 years). METHOD Outcome measures included standardized diagnostic and cognitive assessments and questionnaires on social functioning. Child and adult variables related to current outcomes were explored. RESULTS All individuals continued to meet criteria for autism spectrum disorder (ASD) on the Autism Diagnostic Interview-Revised (ADI-R), but severity of autism symptoms declined over time. Nevertheless, only 10 individuals (17%) were rated as having a "good" or "very good" outcome; the majority (60%) were assessed as having "poor" or "very poor" outcomes. The strongest predictor of adult outcome was the Reciprocal Social Interaction domain score on the ADI at diagnostic confirmation. Change over time was further examined in a subgroup (n = 44) previously assessed 20 years ago earlier (mean age = 26 years). Although severity of autism had continued to decrease during the adult period, social outcomes were poorer than in younger adulthood. CONCLUSIONS In this cohort of adults first diagnosed with autism, on average, 37 years previously, social inclusion remains very limited, despite general improvements in autism symptomatology with age. Whether these findings will be replicated in future generations of children with autism, who now have the benefits of earlier diagnosis and wider access to specialist provision, needs to be the focus of further longitudinal research.
Collapse
|
24
|
Bullock DG, Raymer PL, Savage S. Variation of Protein and Fat Concentration among Commercial Corn Hybrids Grown in the Southeastern USA. ACTA ACUST UNITED AC 2013. [DOI: 10.2134/jpa1989.0157] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- D. G. Bullock
- Dep. of Agronomy, 1102 S. Goodwin Ave.; Univ. of Illinois; Urbana IL 61801
| | - P. L. Raymer
- Agronomy Dep., 1109 Experiment St.; Univ. of Georgia; Griffin GA 30223
| | - S. Savage
- Dep. of Extension Poultry Science, P.O. Box 1209; Univ. of Georgia; Tifton GA 31793
| |
Collapse
|
25
|
Fusaro VA, Brownstein C, Wolf W, Clinton C, Savage S, Mandl KD, Margulies D, Manzi S. Development of a scalable pharmacogenomic clinical decision support service. AMIA Jt Summits Transl Sci Proc 2013; 2013:60. [PMID: 24303299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Advances in sequencing technology are making genomic data more accessible within the healthcare environment. Published pharmacogenetic guidelines attempt to provide a clinical context for specific genomic variants; however, the actual implementation to convert genomic data into a clinical report integrated within an electronic medical record system is a major challenge for any hospital. We created a two-part solution that integrates with the medical record system and converts genetic variant results into an interpreted clinical report based on published guidelines. We successfully developed a scalable infrastructure to support TPMT genetic testing and are currently testing approximately two individuals per week in our production version. We plan to release an online variant to clinical interpretation reporting system in order to facilitate translation of pharmacogenetic information into clinical practice.
Collapse
Affiliation(s)
- Vincent A Fusaro
- Center for Biomedical Informatics, Harvard Medical School, Boston, MA; ; Gene Partnership, Boston Children's Hospital, Boston, MA
| | | | | | | | | | | | | | | |
Collapse
|
26
|
McKinnon C, O'Connor CM, Savage S, Hodges JR, Mioshi E. Qualitative results of a structured group program for carers of people with frontotemporal dementia. Int J Geriatr Psychiatry 2013; 28:217-8. [PMID: 23296839 DOI: 10.1002/gps.3813] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- C. McKinnon
- South Eastern Sydney Local Health District; Sydney; Australia
| | | | - S. Savage
- Neuroscience Research Australia; Sydney; Australia
| | | | | |
Collapse
|
27
|
Brownstein C, Fusaro VA, Savage S, Clinton C, Mandl K, Margulies D, Wolf W, Manzi S. Integration of a standardized pharmacogenomic platform for clinical decision support at Boston Children's Hospital. BMC Proc 2012. [PMCID: PMC3467548 DOI: 10.1186/1753-6561-6-s6-p5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
28
|
Savage S, Mattsson A, Olson L. Cholinergic denervation attenuates phencyclidine-induced c-fos responses in rat cortical neurons. Neuroscience 2012; 216:38-45. [PMID: 22561731 DOI: 10.1016/j.neuroscience.2012.04.064] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Revised: 04/25/2012] [Accepted: 04/26/2012] [Indexed: 12/15/2022]
Abstract
The cortical cholinergic innervation, which is important for memory and cognition, has been implicated in schizophrenia. To experimentally analyze such a possible role of the cholinergic system, we have used the dissociative drug phencyclidine (PCP), known to produce schizophrenia-like psychosis in humans, to model aspects of schizophrenia in rats. We previously showed that induced cortical cholinergic hypofunction leads to enhanced PCP-induced locomotor activity and attenuated social interaction. After PCP, rats lacking cortical cholinergic innervation also show impaired declarative memory. To directly study the role of the basalo-cortical cholinergic projections for PCP-induced neural activation in different cortical areas, we have now monitored the rapid (30 and 60 min) effects of low doses of PCP (2 and 3mg/kg) on neural activation as reflected by transcriptional activation of c-fos in cortical areas, using quantitative in situ hybridization. We find an almost pan-cortical neural induction of c-fos mRNA with doses of PCP low enough not to alter levels of either BDNF or Nogo receptor mRNA levels. Specific unilateral lesioning of the uncrossed cholinergic projections to the cortical mantle by 192-IgG-saporin immunotoxin delivery to nc basalis (NBM) caused a striking ipsilateral decrease of the PCP-induced cortical c-fos mRNA induction, restricted to areas which had become effectively denervated. Because PCP at low doses is unlikely to directly influence cortical neurons, we suggest that it acts by activation of the cholinergic input, which in turn leads to cortical c-fos mRNA increases. Our results are compatible with a role for the cholinergic system in symptoms of schizophrenia, by showing that the basalo-cortical cholinergic projections are needed in order for PCP to have full activating effects on cortical neurons.
Collapse
Affiliation(s)
- S Savage
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
| | | | | |
Collapse
|
29
|
Khan T, Muluneh B, Alexander M, Lasater K, Hoang V, Olson L, Patel R, Mark N, Smith K, Savage S, Poppe L. Evolution of the Pharmacy Practice Model to Improve Patient and Learner Outcomes: A Partnership in Patient Care Initiative (PIPC) in the HSCT Population. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Savage S, Kehr J, Olson L, Mattsson A. Impaired social interaction and enhanced sensitivity to phencyclidine-induced deficits in novel object recognition in rats with cortical cholinergic denervation. Neuroscience 2011; 195:60-9. [DOI: 10.1016/j.neuroscience.2011.08.027] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2011] [Revised: 08/12/2011] [Accepted: 08/13/2011] [Indexed: 11/24/2022]
|
31
|
|
32
|
Hornberger M, Savage S, Hsieh S, Mioshi E, Piguet O, Hodges JR. Orbitofrontal dysfunction discriminates behavioral variant frontotemporal dementia from Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 30:547-52. [PMID: 21252550 DOI: 10.1159/000321670] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/05/2010] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Behavioral variant frontotemporal dementia (bvFTD) patients show prefrontal cortex dysfunction and atrophy. METHODS We investigated whether executive function in conjunction with prefrontal cortex atrophy discriminates bvFTD and Alzheimer's disease (AD) patients efficiently at presentation. RESULTS AD and bvFTD patients were distinguishable by 89.5% on their performance of 3 executive tasks: the Hayling Test of Inhibitory Control, Digit Span Backward and Letter Fluency. Similarly, scan ratings showed that orbitofrontal cortex (OFC) and dorsolateral prefrontal cortex regions distinguish both patient groups. More importantly, employing the Hayling error score in conjunction with the OFC atrophy rating showed that 92% of patients can be correctly classified into bvFTD and AD. CONCLUSION A combination of OFC and disinhibition measures appears to be a powerful diagnostic tool in differentiating bvFTD from AD patients in this preliminary study.
Collapse
Affiliation(s)
- M Hornberger
- Neuroscience Research Australia, Barker & Easy Streets, Randwick, Sydney, NSW 2031, Australia.
| | | | | | | | | | | |
Collapse
|
33
|
Wiśniowiecka-Kowalnik B, Nesteruk M, Peters SU, Xia Z, Cooper ML, Savage S, Amato RS, Bader P, Browning MF, Haun CL, Duda AW, Cheung SW, Stankiewicz P. Intragenic rearrangements in NRXN1 in three families with autism spectrum disorder, developmental delay, and speech delay. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:983-93. [PMID: 20162629 DOI: 10.1002/ajmg.b.31064] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
NRXN1 is highly expressed in brain and has been shown recently to be associated with ASD, schizophrenia, cognitive and behavioral abnormalities, and alcohol and nicotine dependence. We present three families, in whom we identified intragenic rearrangements within NRXN1 using a clinical targeted oligonucleotide array CGH. An approximately 380 kb deletion was identified in a woman with Asperger syndrome, anxiety, and depression and in all four of her children affected with autism, anxiety, developmental delay, and speech delay but not in an unaffected child. An approximately 180 kb tandem duplication was found in a patient with autistic disorder and cognitive delays, and in his mother and younger brother who have speech delay. An approximately 330 kb tandem duplication was identified in a patient with autistic features. As predicted by conceptual translation, all three genomic rearrangements led to the premature truncation of NRXN1. Our data support previous observations that NRXN1 may be pathogenic in a wide variety of psychiatric diseases, including autism spectrum disorder, global developmental delay, anxiety, and depression.
Collapse
|
34
|
|
35
|
Espay A, Dwivedi AK, Vaughan J, Savage S, Sahay A, Duker A, Revilla F, Shukla R. 274 METHYLPHENIDATE FOR THE TREATMENT OF GAIT IMPAIRMENT IN PARKINSON'S DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY (PRELIMINARY RESULTS). Parkinsonism Relat Disord 2010. [DOI: 10.1016/s1353-8020(10)70275-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Shinawi M, Liu P, Kang SHL, Shen J, Belmont JW, Scott DA, Probst FJ, Craigen WJ, Graham BH, Pursley A, Clark G, Lee J, Proud M, Stocco A, Rodriguez DL, Kozel BA, Sparagana S, Roeder ER, McGrew SG, Kurczynski TW, Allison LJ, Amato S, Savage S, Patel A, Stankiewicz P, Beaudet AL, Cheung SW, Lupski JR. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet 2009; 47:332-41. [PMID: 19914906 DOI: 10.1136/jmg.2009.073015] [Citation(s) in RCA: 363] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
BACKGROUND Deletion and the reciprocal duplication in 16p11.2 were recently associated with autism and developmental delay. METHOD We indentified 27 deletions and 18 duplications of 16p11.2 were identified in 0.6% of all samples submitted for clinical array-CGH (comparative genomic hybridisation) analysis. Detailed molecular and phenotypic characterisations were performed on 17 deletion subjects and ten subjects with the duplication. RESULTS The most common clinical manifestations in 17 deletion and 10 duplication subjects were speech/language delay and cognitive impairment. Other phenotypes in the deletion patients included motor delay (50%), seizures ( approximately 40%), behavioural problems ( approximately 40%), congenital anomalies ( approximately 30%), and autism ( approximately 20%). The phenotypes among duplication patients included motor delay (6/10), behavioural problems (especially attention deficit hyperactivity disorder (ADHD)) (6/10), congenital anomalies (5/10), and seizures (3/10). Patients with the 16p11.2 deletion had statistically significant macrocephaly (p<0.0017) and 6 of the 10 patients with the duplication had microcephaly. One subject with the deletion was asymptomatic and another with the duplication had a normal cognitive and behavioural phenotype. Genomic analyses revealed additional complexity to the 16p11.2 region with mechanistic implications. The chromosomal rearrangement was de novo in all but 2 of the 10 deletion cases in which parental studies were available. Additionally, 2 de novo cases were apparently mosaic for the deletion in the analysed blood sample. Three de novo and 2 inherited cases were observed in the 5 of 10 duplication patients where data were available. CONCLUSIONS Recurrent reciprocal 16p11.2 deletion and duplication are characterised by a spectrum of primarily neurocognitive phenotypes that are subject to incomplete penetrance and variable expressivity. The autism and macrocephaly observed with deletion and ADHD and microcephaly seen in duplication patients support a diametric model of autism spectrum and psychotic spectrum behavioural phenotypes in genomic sister disorders.
Collapse
Affiliation(s)
- Marwan Shinawi
- Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, NAB 2015, Houston, Texas 77030, USA;
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Lillo P, Savage S, Hsieh S, Mioshi E, Leyton C, Hodges J. FP49-TH-01 Behavioural changes and cognitive impairment in motor neurone disease. J Neurol Sci 2009. [DOI: 10.1016/s0022-510x(09)70528-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
38
|
Pant S, Hostetter G, Armstrong B, Bittner M, Shack S, Savage S, Weiss GJ, Ozer H, Ramanathan R. Use of independent genome-wide assays to discover HOXA signature in colon and rectal cancers and validate a role in tumorigenesis. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15014 Background: Rectal cancer differs from colon cancer in terms of prognosis. Here we present genome-wide expression analysis of 79 colon and rectal tumors and gene dosage analysis of 34 archival colorectal tumors in paraffin (FFPE). Methods: Expression data were acquired ( http://expo.intgen.org/geo/home.do ) from Affymetrix experiments analyzed with GeneSpring software version 7.3 (Silicon Genetics, CA). Expression data were normalized ’per chip’ normalized to the 50th percentile of all values; and ’per gene’ normalized to the median expression level across all samples. Expression Project for Oncology (expO) samples included colon (n=50) and rectum (n=29). Differentially expressed genes were identified by parametric test for which variances were not assumed equal (Welch ANOVA). Array comparative genomic hybridization (aCGH) were performed separately on an independent set of FFPE colorectal tumors (n=34) by 244 K microarrays for CGH, Agilent Technologies, CA and with platform embedded analyses tools of CGH Analytics software and ADM-1 bioinformatics. Functional assay by knockout of HOXA9 promoter by lentiviral sh-RNAi construct was performed on colon cancer cell lines shown to have increased HOXA9 dosage and expression. Results: The analysis of expO colon and rectal cancers generated 42 genes with significant differential expression, 26 showed an increased expression of > 2 fold in colon versus rectal samples. Transcription factor family HOXA9 was the most highly expressed (3.8 fold) in colon versus rectal cancer. The aCGH data showed a low level gain of the HOXA gene to be the most frequent dosage alteration (38%). Validation by IHC and qRT-PCR showed 80% and 76% concordance, respectively. Functional assay by sh-RNAi in cell lines (compared to vehicle only) showed marked decrease in cellular viability (40 to 60%), marked morphologic change and a significantly increased apoptotic rate. Conclusion: Multiple genome-wide assays have identified HOXA9 as differentially dosed and expressed in colon and rectal tumors. Compelling functional data from sh-RNAi experiments suggests a tumorigenic role for HOXA9 in altered apoptosis. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Pant
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - G. Hostetter
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - B. Armstrong
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - M. Bittner
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - S. Shack
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - S. Savage
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - G. J. Weiss
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - H. Ozer
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | - R. Ramanathan
- University Of Oklahoma Health Sciences Center, Oklahoma City, OK; Translational Genomics Research Institute, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| |
Collapse
|
39
|
Oetting WS, Pietsch J, Brott MJ, Savage S, Fryer JP, Summers CG, King RA. The R402Q tyrosinase variant does not cause autosomal recessive ocular albinism. Am J Med Genet A 2009; 149A:466-9. [DOI: 10.1002/ajmg.a.32654] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
40
|
Nixon A, Allen J, Miller E, Savage S, Kaplan N, Starr M, Bendell J, Uronis H, Fernando N, Hurwitz H. Clinical evaluation of nitric oxide responses to anti-VEGF therapy with bevacizumab. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14039 Background: Anti-vascular endothelial growth factor (anti-VEGF) therapy has been linked to hypertension (HTN) and arterial thrombo-embolic events that may involve changes in nitric oxide (NO) bioavailability. Methods: 25 patients (pts) with advanced cancer, normal renal function and blood pressure (BP), no increased risks for anti-VEGF toxicities, and not on medications known to confound biomarker studies (including anti-hypertensives) were treated with bevacizumab (BV) 15mg/kg d1, then 10mg/kg q2 week. Prior to biomarker assessment, all patients were placed on a calorie-, nitrate-, and salt-restricted diet for 72 hr. All measures were taken pre-treatment (preRx) and on day 28 of treatment (onRx). Dependant variables included; a) Brachial artery reactivity (BAR) following hyperemic flow stimulus (endothelium-dependent) and sub-lingual nitroglycerine (NTG; endothelium-independent); b) exhaled and plasma/urine total NO2/NO3 using chemiluminescence (Sievers 280NOA) with either KI or VCl3 in HCl as the reductants; c) blood pressure. Additionally, we measured multiple regulators of vascular tone and injury. Comparisons were analyzed using Spearman signed rank tests. Results: Of 25 pts (16 F, 9 M) treated, 21 patients were fully evaluable. Significant changes or strong trends were observed upon comparing preRx vs. onRx for BP (SBP +12.4, DBP +5.6, MAP +7.9 mm Hg), and flow-mediated BAR (-2.0%) with no changes in hyperemic flow/shear stimulus or smooth muscle function (BAR NTG), indicating a decrease in brachial artery endothelial responsiveness. Exhaled NO decreased (-0.8% d1vs d28 and -0.6% pre/post infusion day1). Measurement and data analysis of urinary/plasma NO2/NO3, as well as angiogenic markers, are almost complete and will be reported. Conclusions: After one month of treatment, BV increased BP and decreased endothelium- dependent BAR and exhaled NO, suggesting potentially broad, mechanism-based effects on NO bioavailability in patients. [Table: see text]
Collapse
Affiliation(s)
- A. Nixon
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - J. Allen
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - E. Miller
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - S. Savage
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - N. Kaplan
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - M. Starr
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - J. Bendell
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - H. Uronis
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - N. Fernando
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| | - H. Hurwitz
- Duke University Medical Center, Durham, NC; Georgia Cancer Specialists, Cumming, GA
| |
Collapse
|
41
|
Dejonge M, Savage S, Verweij J, Collins TS, Eskens F, Whitehead B, Suttle AB, Pandite LB, Ho PT, Hurwitz H. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3088] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3088 Background: P is a potent tyrosine kinase inhibitor of VEGF-R1, -R2, and R3, PDGF-α/β, and c-Kit. L is a potent inhibitor of ErbB1 and ErbB2 tyrosine kinases. Several lines of evidence support combined inhibition of VEGFR and Erb in the treatment of malignancies. Methods: Patients (pts) with solid tumors received P and L daily. Safety, limited PK, biomarkers, and clinical activity were evaluated. Dose escalation occurred in cohorts of 3–6 pts based on DLT. Results: Thirty-three pts received L/P doses of 750/250 (n=4), 750/500 (n=6), 1000/250 (n=3), 1000/400 (n=2), 1000/500 (n=4), 1250/250 (n=6), 1250/400 (n=5) and 1500/200 (n=3) mg once daily (qd). Preliminary mean plasma P concentrations 24 h after administration (C24) on Day 22 were ∼19 μg/mL and 23 μg/mL after administration of 250 mg and 500 mg, respectively. These values are similar to mean C24 values observed after administration of 800 mg P alone (23.1 μg/mL). Plasma L concentrations at 750 - 1500 mg qd were similar to those observed after monotherapy. The most frequent AE’s were diarrhea (Grade (G)1 n=10, G2 n=2, G3 n=3), fatigue (G1: n=7, G2 n=5, G4 n=1), nausea (G1 n=9, G2 n=2), anorexia (G1 n=8, G2 n=3), vomiting (G1 n=9), hair depigmentation (n=7), rash (G1 n=6, G2 n=1) and abdominal cramps (G1 n=3, G2 n=2, G3 n=1). Prolonged disease stabilization of > 16 wks (median 21.5 wks) occurred in 10 pts (RCC n=3, CRC n=3, GIST n=1, mesothelioma n=1, adenocarcinoma GE junction n=1, aggressive fibromatosis n=1). 3 pts (renal cancer n=2, and giant cell tumor of the bone n=1) demonstrated tumor shrinkage of < 30% (i.e. SD by RECIST). Conclusions: Concurrent administration of pazopanib and lapatinib was generally well tolerated. Coadministration of lapatinib may alter the PK of pazopanib. [Table: see text]
Collapse
Affiliation(s)
- M. Dejonge
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - S. Savage
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - J. Verweij
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - T. S. Collins
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - F. Eskens
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - B. Whitehead
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - A. B. Suttle
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - L. B. Pandite
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - P. T. Ho
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| | - H. Hurwitz
- Erasmus Medical Center, Rotterdam, Netherlands Antilles; Duke Comprehensive Cancer Center, Durham, NC; GlaxoSmithKline, Durham, NC; GlaxoSmithKline, Upper Providence, PA
| |
Collapse
|
42
|
Sofocleous CT, Brown KT, Savage S, Brogi E, Covey AM, Brody LA, Schubert J, Getrajdman GI. Upper urinary tract metastases from adenocarcinoma of the colon. Acta Radiol 2005; 46:437-40. [PMID: 16134324 DOI: 10.1080/02841850510021229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
An unusual presentation of colorectal metastasis to the upper urinary tract is reported. The metastasis manifested as a filling defect seen during antegrade pyelography. Cytologic evaluation of aspirated material demonstrated metastatic colonic adenocarcinoma. A dilated collecting system may be caused by intraluminal material including tumor and blood clots. Whenever fixed filling defects are encountered, urine cytology should be sent even in the absence of renal parenchymal involvement by tumor. The cytological evaluation may allow for prompt diagnosis and treatment.
Collapse
Affiliation(s)
- C T Sofocleous
- Memorial Sloan Kettering Cancer Center, Image Guided Therapies and Interventional Radiology, 1275 York Avenue, New York, NY 10021, USA.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Hurwitz H, Dowlati A, Savage S, Fernando N, Lasalvia S, Whitehead B, Suttle B, Collins D, Ho P, Pandite L. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3012] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Hurwitz
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - A. Dowlati
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - S. Savage
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - N. Fernando
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - S. Lasalvia
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - B. Whitehead
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - B. Suttle
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - D. Collins
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - P. Ho
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| | - L. Pandite
- Duke Univ, Durham, NC; Case Western Reserve, Cleveland, OH; GlaxoSmithKline, Durham, NC
| |
Collapse
|
44
|
Suttle AB, Hurwitz H, Dowlati A, Fernando N, Savage S, Coviello K, Dar M, Ertel P, Whitehead B, Pandite L. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. B. Suttle
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - H. Hurwitz
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - A. Dowlati
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - N. Fernando
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - S. Savage
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - K. Coviello
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - M. Dar
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - P. Ertel
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - B. Whitehead
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| | - L. Pandite
- GlaxoSmithKline, Research Triangle Park, NC; Duke University Medical Center, Durham, NC; Case Western Reserve University, Cleveland, OH
| |
Collapse
|
45
|
King RA, Pietsch J, Fryer JP, Savage S, Brott MJ, Russell-Eggitt I, Summers CG, Oetting WS. Tyrosinase gene mutations in oculocutaneous albinism�1 (OCA1): definition of the phenotype. Hum Genet 2003; 113:502-13. [PMID: 13680365 DOI: 10.1007/s00439-003-0998-1] [Citation(s) in RCA: 88] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2003] [Accepted: 06/29/2003] [Indexed: 10/26/2022]
Abstract
Oculocutaneous albinism (OCA) is a common human genetic condition resulting from mutations in at least twelve different genes. OCA1 results from mutations of the tyrosinase gene and presents with the life-long absence of melanin pigment after birth (OCA1A) or with the development of minimal-to-moderate amounts of cutaneous and ocular pigment (OCA1B). Other types of OCA have variable amounts of cutaneous and ocular pigment. We hypothesized that white hair at birth indicates OCA1 and tested this in a sample of 120 probands with OCA and white hair at birth. We found that 102 (85%) of the probands had OCA1 with one or two identifiable tyrosinase gene mutations, with 169 (83%) of the 204 OCA1 tyrosinase gene alleles having identifiable mutations and 35 (17%) having no identifiable change in the coding, splice junction, or proximal promoter regions of the gene. The inability to identify the mutation was more common with OCA1B (24/35, 69%) than with OCA1A (11/35, 31%) alleles. Seven probands with no tyrosinase gene mutations were found to have OCA2 with one or two P gene mutations, and in eleven, no mutations were detected in either gene. We conclude that (1) the presence of white hair at birth is a useful clinical tool suggesting OCA1 in a child or adult with OCA, although OCA2 may also have this presentation; (2) the molecular analysis of the tyrosinase and P genes are necessary for precise diagnosis; and (3) the presence of alleles without identifiable mutations of the tyrosinase gene, particularly in OCA1B, suggests that more complex mutation mechanisms of this gene are common in OCA.
Collapse
Affiliation(s)
- Richard A King
- Department of Medicine, University of Minnesota, Minneapolis, Minn. 55455, USA.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
King RA, Willaert RK, Schmidt RM, Pietsch J, Savage S, Brott MJ, Fryer JP, Summers CG, Oetting WS. MC1R mutations modify the classic phenotype of oculocutaneous albinism type 2 (OCA2). Am J Hum Genet 2003; 73:638-45. [PMID: 12876664 PMCID: PMC1180688 DOI: 10.1086/377569] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2003] [Accepted: 06/17/2003] [Indexed: 11/03/2022] Open
Abstract
The heterogeneous group of disorders known as oculocutaneous albinism (OCA) shares cutaneous and ocular hypopigmentation associated with common developmental abnormalities of the eye. Mutations of at least 11 loci produce this phenotype. The majority of affected individuals develop some cutaneous melanin; this is predominantly seen as yellow/blond hair, whereas fewer have brown hair. The OCA phenotype is dependent on the constitutional pigmentation background of the family, with more OCA pigmentation found in families with darker constitutional pigmentation, which indicates that other genes may modify the OCA phenotype. Sequence variation in the melanocortin-1 receptor (MC1R) gene is associated with red hair in the normal population, but red hair is unusual in OCA. We identified eight probands with OCA who had red hair at birth. Mutations in the P gene were responsible for classic phenotype of oculocutaneous albinism type 2 (OCA2) in all eight, and mutations in the MC1R gene were responsible for the red (rather than yellow/blond) hair in the six of eight who continued to have red hair after birth. This is the first demonstration of a gene modifying the OCA phenotype in humans.
Collapse
Affiliation(s)
- Richard A King
- Department of Genetics, University of Minnesota, Minneapolis, MN, 55455, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
The allocation of resources to providers and the way in which the resources are then prioritised to specific service areas and patients remain the critical ethical decisions which determine the type of health system a community receives. Health care providers will never be given enough resources to satisfy all the demands placed upon them by a community that is becoming increasingly informed and demanding. This paper discusses the matter of justice as it relates to the distribution of health resources. It translates the theoretical constructs of distribution into a practical situation that arose at The Geelong Hospital. It is important to emphasise that the aim of giving the example is not necessarily to provide the right answer but rather to assist in determining what ought to be the questions.
Collapse
Affiliation(s)
- S Capp
- Barwon Health, Geelong, Victoria
| | | | | |
Collapse
|
48
|
Lloyd Spetz A, Un�us L, Svenningstorp H, Tobias P, Ekedahl LG, Larsson O, G�ras A, Savage S, Harris C, M�rtensson P, Wigren R, Salomonsson P, H�ggendahl B, Ljung P, Mattsson M, Lundstr�m I. SiC Based Field Effect Gas Sensors for Industrial Applications. ACTA ACUST UNITED AC 2001. [DOI: 10.1002/1521-396x(200105)185:1<15::aid-pssa15>3.0.co;2-7] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
49
|
Abstract
Twenty (20) people who had medically diagnosed fibromyalgia for two to 15+ years participated in and completed a 90-day evaluation to determine effects of collagen hydrolysat on symptoms of chronic fibromyalgia, with twelve reporting temporomandibular joint pain. Collagen hydrolysat is a food supplement that is available without prescription, with no known side effects. Participants were evaluated initially and then at 30-, 60-, and 90-day periods. Final results were obtained and comparisons made. The average pain complaint levels decreased significantly in an overall group average, and dramatically with some individuals. It was concluded that patients with fibromyalgia and concurrent temporomandibular joint problems may gain symptomatic improvement in their chronic symptoms by taking collagen hydrolysat.
Collapse
|
50
|
Savage S. Consumer durable. Interview by Heather Stephen. Nurs Stand 1999; 13:18-9. [PMID: 10497539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
|